Manufacturing has been widely recognized as a bottleneck to bring advanced cell and gene therapies to the patients and families in need. The question is, should organizations stay the course internally, or look externally for their manufacturing needs?
Congratulations to PRECISIONadvisors and PRECISIONheor for presenting more than a dozen posters and panels at Virtual ISPOR Europe 2020, 16 - 19 November, 2020.
Congratulations to Precision Medicine Group Co-Founder and CEO Mark Clein on his moderated Point: Counterpoint panel at this year’s HLTH Conference.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
